Lung cancer genotype-based therapy and predictive biomarkers present and future

Philip T. Cagle, Timothy Craig Allen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.

Original languageEnglish (US)
Pages (from-to)1482-1491
Number of pages10
JournalArchives of Pathology and Laboratory Medicine
Volume136
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Lung Neoplasms
Precision Medicine
Biomarkers
Genotype
Molecular Targeted Therapy
Peer Review
Information Storage and Retrieval
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Therapeutics
Immunohistochemistry
Mutation
Antibodies
Pathologists
anaplastic lymphoma kinase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Lung cancer genotype-based therapy and predictive biomarkers present and future. / Cagle, Philip T.; Allen, Timothy Craig.

In: Archives of Pathology and Laboratory Medicine, Vol. 136, No. 12, 12.2012, p. 1482-1491.

Research output: Contribution to journalArticle

Cagle, Philip T. ; Allen, Timothy Craig. / Lung cancer genotype-based therapy and predictive biomarkers present and future. In: Archives of Pathology and Laboratory Medicine. 2012 ; Vol. 136, No. 12. pp. 1482-1491.
@article{41fde1a5a0d64909b83d40ddb9846292,
title = "Lung cancer genotype-based therapy and predictive biomarkers present and future",
abstract = "Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.",
author = "Cagle, {Philip T.} and Allen, {Timothy Craig}",
year = "2012",
month = "12",
doi = "10.5858/arpa.2012-0508-RA",
language = "English (US)",
volume = "136",
pages = "1482--1491",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

TY - JOUR

T1 - Lung cancer genotype-based therapy and predictive biomarkers present and future

AU - Cagle, Philip T.

AU - Allen, Timothy Craig

PY - 2012/12

Y1 - 2012/12

N2 - Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.

AB - Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84870858928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870858928&partnerID=8YFLogxK

U2 - 10.5858/arpa.2012-0508-RA

DO - 10.5858/arpa.2012-0508-RA

M3 - Article

VL - 136

SP - 1482

EP - 1491

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -